These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 31037455)

  • 1. Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data.
    Xue L; Zhang Y; Xie C; Zhou L; Liu L; Zhang H; Xu L; Song H; Lin M; Qiu H; Zhu J; Zhu Y; Zou J; Zhuang W; Xuan B; Chen Y; Fan Y; Wu D; Shen Z; Miao L
    Eur J Clin Pharmacol; 2019 Jun; 75(6):785-794. PubMed ID: 31037455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.
    Xue L; Holford N; Ding XL; Shen ZY; Huang CR; Zhang H; Zhang JJ; Guo ZN; Xie C; Zhou L; Chen ZY; Liu LS; Miao LY
    Br J Clin Pharmacol; 2017 Apr; 83(4):823-835. PubMed ID: 27763679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study.
    Gemmati D; Burini F; Talarico A; Fabbri M; Bertocco C; Vigliano M; Moratelli S; Cuneo A; Serino ML; Avato FM; Tisato V; Gaudio RM
    PLoS One; 2016; 11(9):e0162084. PubMed ID: 27606428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.
    Sasaki T; Tabuchi H; Higuchi S; Ieiri I
    Pharmacogenomics; 2009 Aug; 10(8):1257-66. PubMed ID: 19663670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new regimen for starting warfarin therapy in out-patients.
    Oates A; Jackson PR; Austin CA; Channer KS
    Br J Clin Pharmacol; 1998 Aug; 46(2):157-61. PubMed ID: 9723825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery.
    Abohelaika S; Wynne H; Avery P; Kamali F
    J Thromb Haemost; 2015 Aug; 13(8):1436-40. PubMed ID: 26010205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population.
    Holm J; Lindh JD; Andersson ML; Mannheimer B
    J Thromb Haemost; 2017 Mar; 15(3):446-453. PubMed ID: 28058824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
    Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
    Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.